Gianclaudio Floria, senior manager for business planning and analysis at Amgen, on best practice in forecasting for orphan drug development.
(Jul 8, 2010)Kenneth Youngstein, CEO of Biocom, on the regulatory, strategic, and tactical challenges of cross-border compliance programs.
(Aug 23, 2010)*Angelo DePalma reports on how personalized medicine may further weaken the blockbuster model of drug development but open up lucrative new niche markets*
(Dec 8, 2010)*Pharma is unprepared for the blockbuster patent expirations due over the next few years. Angelo DePalma argues that innovation is the only strategic solution*
(Feb 3, 2011)*Anonymous patient-level data (APLD) is an attractive information source for pharma marketers, but its acquisition and use are complex.*
(Feb 14, 2011)Angelo DePalma investigates how emerging collaborative partnerships could alter how drug firms manage innovation and market new medicines
(Jun 5, 2011)Pharma firms are betting that branded generics will become a powerful source of revenue, particularly in emerging markets. Angelo DePalma reports
(Jul 4, 2011)Angelo DePalma outlines the prospects for the global market for pain management pharmaceuticals and devices
(Jul 26, 2011)Kevin Appareti, global director for Medical Science Liaison at Philips Healthcare, explains how to motivate KOLs and how to measure their value
The Mobile Health Competition is now closed, but the journey is just beginning for the winning idea.
Phil Taylor reports on the commercial and scientific opportunities facing medical scientific liaisons (MSLs)
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs